Proteomics

Dataset Information

0

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

ABSTRACT: The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumor tissues of 26 RCC patients were analyzed. Eight patients were primary resistant (RES) and 18 sensitive (SENS).

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Kidney

SUBMITTER: Thang Pham  

LAB HEAD: Connie Jimenez

PROVIDER: PXD043514 | Pride | 2024-01-26

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
QE2_150824_OPL1013_RdH_MLA_RCC_SU_LYSATE_AAA.raw Raw
QE2_150824_OPL1013_RdH_MLA_RCC_SU_LYSATE_BBB.raw Raw
QE2_150824_OPL1013_RdH_MLA_RCC_SU_LYSATE_CCC.raw Raw
QE2_150824_OPL1013_RdH_MLA_RCC_SU_LYSATE_DDD.raw Raw
QE2_150824_OPL1013_RdH_MLA_RCC_SU_LYSATE_EEE.raw Raw
Items per page:
1 - 5 of 67
altmetric image

Publications

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics.

van der Wijngaart Hanneke H   Beekhof Robin R   Knol Jaco C JC   Henneman Alex A AA   de Goeij-de Haas Richard R   Piersma Sander R SR   Pham Thang V TV   Jimenez Connie R CR   Verheul Henk M W HMW   Labots Mariette M  

Clinical proteomics 20231108 1

The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumor tissues of 26 RCC patients were analyzed. Eight patients had primary resistant (RES) and 18 sensitive (SENS) RCC. A 78 phosphosite signature (p < 0.05, fold-change > 2) was identified; 22 p-sites we  ...[more]

Similar Datasets

Proteomics Transgelin contributes to a poor response of metastatic renal cell carcinoma to sunitinib treatment
2021-11-03 | PXD027065 | Pride
Proteomics Differential activity of treatment with protein kinase inhibitors on tumor phosphotyrosine profiles in patients with advanced cancer
2019-04-18 | PXD008032 | Pride
Proteomics Proteomic data for tumor pericytes derived from colorectal cancer patients
2024-01-26 | PXD033011 | Pride
Proteomics Evaluation of phospho-tyrosine antibodies for label-free phosphoproteomics
2015-12-09 | PXD001565 | Pride
Models dePillis2013 - Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment
2024-09-02 | BIOMD0000000908 | BioModels
Proteomics Label-free quantitative phosphoproteomics of sunitinib-resistant renal cell carcinoma upon estrogen treatment
2020-08-07 | PXD011020 | Pride
Proteomics Phosphoproteomics scaled-down to tumor biopsy level -part 1 cell line
2022-03-02 | PXD003808 | Pride
Proteomics Phosphoproteomics scaled-down to tumor biopsy level. Part 2: biopsies
2019-10-28 | PXD003814 | Pride
Proteomics Fibrinogen chain positive circulating exosomes are a colorectal cancer potential biomarker
2020-05-26 | PXD009490 | Pride
Transcriptomics Effect of depletion of FUS on gene expression during in sunitinib-resistance cell lines
2023-03-31 | GSE226245 | GEO